title: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
abstract: The receptor for advanced glycation end products (RAGE), a multi-ligand member of the immunoglobulin superfamily of cell surface molecules, interacts with distinct molecules implicated in homeostasis, development and inflammation, and certain diseases such as diabetes and Alzheimer's disease. Engagement of RAGE by a ligand triggers activation of key cell signalling pathways, such as p21ras, MAP kinases, NF-kappaB and cdc42/rac, thereby reprogramming cellular properties. RAGE is a central cell surface receptor for amphoterin, a polypeptide linked to outgrowth of cultured cortical neurons derived from developing brain. Indeed, the co-localization of RAGE and amphoterin at the leading edge of advancing neurites indicated their potential contribution to cellular migration, and in pathologies such as tumour invasion. Here we demonstrate that blockade of RAGE-amphoterin decreased growth and metastases of both implanted tumours and tumours developing spontaneously in susceptible mice. Inhibition of the RAGE-amphoterin interaction suppressed activation of p44/p42, p38 and SAP/JNK MAP kinases; molecular effector mechanisms importantly linked to tumour proliferation, invasion and expression of matrix metalloproteinases.
authors.affiliation: College of Physicians & Surgeons, Columbia University, New York, New York 10032, USA.
authors.forename: A
authors.initials: A
authors.lastname: Taguchi
authors.forename: D C
authors.initials: DC
authors.lastname: Blood
authors.forename: G
authors.initials: G
authors.lastname: del Toro
authors.forename: A
authors.initials: A
authors.lastname: Canet
authors.forename: D C
authors.initials: DC
authors.lastname: Lee
authors.forename: W
authors.initials: W
authors.lastname: Qu
authors.forename: N
authors.initials: N
authors.lastname: Tanji
authors.forename: Y
authors.initials: Y
authors.lastname: Lu
authors.forename: E
authors.initials: E
authors.lastname: Lalla
authors.forename: C
authors.initials: C
authors.lastname: Fu
authors.forename: M A
authors.initials: MA
authors.lastname: Hofmann
authors.forename: T
authors.initials: T
authors.lastname: Kislinger
authors.forename: M
authors.initials: M
authors.lastname: Ingram
authors.forename: A
authors.initials: A
authors.lastname: Lu
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: O
authors.initials: O
authors.lastname: Hori
authors.forename: S
authors.initials: S
authors.lastname: Ogawa
authors.forename: D M
authors.initials: DM
authors.lastname: Stern
authors.forename: A M
authors.initials: AM
authors.lastname: Schmidt
mesh_terms: D000818:Animals; D001973:Bromodeoxyuridine / Q000378:metabolism; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D024243:HMGB1 Protein; D006609:High Mobility Group Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D020935:MAP Kinase Signaling System; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D016513:Mice, SCID; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D051381:Rats; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D002352:Carrier Proteins; D024243:HMGB1 Protein; D006609:High Mobility Group Proteins; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D001973:Bromodeoxyuridine